Cyprotex
Ralf Geiben Lynn, currently working as the Associate Vice President Business Development at Cyprotex, is an experienced professional in the biotechnology and pharmaceutical industry. With a background in biology and business, Ralf has held various leadership positions in companies focused on drug development, biophysics, and immunomodulation. Ralf has also been involved in biomarker development, virus/host interactions, and vaccine evaluation during their tenure at prestigious institutions like Harvard Medical School and Massachusetts General Hospital. With a strong track record of founding and leading companies, Ralf brings a wealth of knowledge and expertise to their current role at Cyprotex.
This person is not in any offices
Cyprotex
Founded in 1999, Cyprotex (www.cyprotex.com) has grown to become an industry leader in in vitro and in silico ADME-Tox. The company, with sites in the UK and USA, was acquired by Evotec (www.evotec.com) in 2016. The Evotec Group offer expert support from early discovery through to clinical development. * High-throughput ADME screening * Customised ADME assays * In silico ADME predictive modeling * In vitro toxicology